RT Journal Article
SR Electronic
T1 ▼Etanercept and ▼infliximab for rheumatoid arthritis
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 49
OP 52
DO 10.1136/dtb.2001.39749
VO 39
IS 7
YR 2001
UL http://dtb.bmj.com/content/39/7/49.abstract
AB Relevant BNF section: 10.1.3&#9660Etanercept* (Enbrel - Wyeth) and&#9660infliximab* (Remicade - Schering Plough) belong to a new class of drugs that block the effects of tumour necrosis factor-alpha (TNF-α), a mediator of inflammation. Both are licensed for the treatment of patients with active rheumatoid arthritis who have responded inadequately to disease-modifying antirheumatic drugs (DMARDs). Here, we consider whether etanercept and infliximab offer advantages.